--- title: "ATYR Pharma | 10-Q: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/286607066.md" datetime: "2026-05-15T20:05:57.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286607066.md) - [en](https://longbridge.com/en/news/286607066.md) - [zh-HK](https://longbridge.com/zh-HK/news/286607066.md) --- # ATYR Pharma | 10-Q: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -0.11, beating the estimate of USD -0.1457. aTyr Pharma, Inc. operates as a single segment and has incurred net losses and negative cash flows from operations since its inception in 2005, with an accumulated deficit of -$617.0 million as of March 31, 2026. #### Consolidated Net Loss For the three months ended March 31, 2026, the consolidated net loss was -$10,792 thousand, which is an improvement compared to -$14,881 thousand for the same period in 2025. #### Research and Development Expenses Total research and development expenses decreased by $4,497 thousand, from $11,814 thousand for the three months ended March 31, 2025, to $7,317 thousand for the same period in 2026. This decrease was primarily driven by a $5,269 thousand reduction in efzofitimod expenses, which fell from $8,804 thousand in 2025 to $3,535 thousand in 2026 due to the completion of the EFZO-FIT study and decreased manufacturing costs. Conversely, preclinical development and other shared research and development expenses increased by $795 thousand, from $2,560 thousand in 2025 to $3,355 thousand in 2026, mainly due to increased discovery costs for preclinical product candidates. Non-cash expenses for research and development remained consistent at $427 thousand in 2026 and $450 thousand in 2025. #### General and Administrative Expenses Total general and administrative expenses increased by $160 thousand, from $3,959 thousand for the three months ended March 31, 2025, to $4,119 thousand for the same period in 2026. Other general and administrative expenses remained consistent at $3,076 thousand in 2026 and $3,064 thousand in 2025. Non-cash expenses increased by $148 thousand, from $895 thousand in 2025 to $1,043 thousand in 2026, primarily due to increased non-cash stock-based compensation expenses. #### Other Income (Expense), Net Other income (expense), net was $644 thousand for the three months ended March 31, 2026, a decrease from $892 thousand for the same period in 2025, mainly due to lower interest rates and reduced interest earned on lower cash balances. #### Cash Flows Net cash used in operating activities was -$12,517 thousand for the three months ended March 31, 2026, an improvement from -$15,420 thousand for the same period in 2025. Net cash provided by investing activities was $11,494 thousand for the three months ended March 31, 2026, a significant change from net cash used in investing activities of -$4,420 thousand for the same period in 2025. Net cash used in financing activities was -$142 thousand for the three months ended March 31, 2026, compared to net cash provided by financing activities of $18,628 thousand for the same period in 2025. Cash, cash equivalents and restricted cash totaled $11,813 thousand at March 31, 2026, down from $12,794 thousand at March 31, 2025. #### Liquidity and Capital Resources As of March 31, 2026, aTyr Pharma, Inc. had cash, cash equivalents, restricted cash, and available-for-sale investments totaling $68.3 million, which are believed to be sufficient to meet material cash requirements for at least one year from the filing date of the Quarterly Report. The company did not utilize its Jefferies ATM Offering Program during the three months ended March 31, 2026. #### Future Outlook and Strategy aTyr Pharma, Inc. plans to continue the development of efzofitimod in pulmonary sarcoidosis with a planned Phase 3 study, which will use FVC as the primary endpoint and KSQ-Lung score as the key secondary endpoint, focusing on patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease, and will involve increasing the dosing frequency of efzofitimod to once every three weeks. The planned Phase 3 study and any additional clinical trials for efzofitimod will require significant time and resources, necessitating additional capital through equity offerings or partnering. On May 12, 2026, Kyorin Pharmaceutical Co., Ltd. terminated its collaboration and license agreement with aTyr Pharma, Inc., resulting in aTyr Pharma, Inc. no longer being entitled to $155.0 million in potential milestone payments and royalties but regaining global rights to develop and commercialize efzofitimod. ### Related Stocks - [ATYR.US](https://longbridge.com/en/quote/ATYR.US.md) ## Related News & Research - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Correction: NextNRG to Host First Quarter 2026 Financial Results Conference Call on May 18, 2026 at 9:00 a.m. ET | NXXT Stock News](https://longbridge.com/en/news/286673001.md) - [Keysight Technologies Reports Second Quarter 2026 Results | KEYS Stock News](https://longbridge.com/en/news/286959830.md) - [The Seed 40: The best women early-stage investors of 2026](https://longbridge.com/en/news/286743171.md)